Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD

4.160

+0.105 (2.59%)

At close: Jul 19, 2024, 4:30 PM

4.100

-0.060 (-1.44%)

Pre-market: Jul 22, 2024, 4:10 AM EDT

Relmada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2015
Selling, General & Admin	46.28	48.89	47.93	35.08	24.87	7.25	Upgrade
Research & Development	52.25	54.81	113.32	90.62	35.97	7.86	Upgrade
Operating Expenses	98.54	103.7	161.25	125.7	60.84	15.11	Upgrade
Operating Income	-98.54	-103.7	-161.25	-125.7	-60.84	-15.11	Upgrade
Interest Expense / Income	0	0	0	0	0	0.1	Upgrade
Other Expense / Income	-4.24	-4.91	-4.21	0.05	-1.38	-0.21	Upgrade
Pretax Income	-94.3	-98.79	-157.04	-125.75	-59.46	-15.01	Upgrade
Net Income	-94.3	-98.79	-157.04	-125.75	-59.46	-15.01	Upgrade
Shares Outstanding (Basic)	30	30	30	18	16	9	Upgrade
Shares Outstanding (Diluted)	30	30	30	18	16	9	Upgrade
Shares Change	0.11%	1.59%	68.80%	12.56%	68.75%	194.65%	Upgrade
EPS (Basic)	-3.12	-3.28	-5.30	-7.16	-3.81	-1.62	Upgrade
EPS (Diluted)	-3.12	-3.28	-5.30	-7.16	-3.81	-1.62	Upgrade
Free Cash Flow	-48.19	-51.66	-103.8	-91.87	-27.81	-12.09	Upgrade
Free Cash Flow Per Share	-1.60	-1.72	-3.50	-5.23	-1.78	-1.31	Upgrade
EBITDA	-94.3	-98.79	-157.04	-125.75	-59.45	-14.9	Upgrade
Depreciation & Amortization	0	0	0	0	0	0	Upgrade
EBIT	-94.3	-98.79	-157.04	-125.75	-59.46	-14.9	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).